Objective: To investigate whether certain CSF biomarkers at baseline can predict future progression of motor symptoms and cognitive decline in patients with Parkinson disease (PD).
predictor of subsequent development of cognitive decline in patients with PD without dementia. [7] [8] [9] [10] However, another recent study found that increased baseline levels of aSyn, but not b-amyloid, are associated with future decline in cognitive function. 11 The objective of the present study was to perform a prospective and longitudinal study designed to investigate the associations between all of the most established CSF biomarkers, including aSyn, Ab 42 , tau, p-tau, and neurofilament light (NFL, a marker of injury to or degeneration of large caliber myelinated axons) and subsequent progression of both motor symptoms as well as cognitive decline in PD. 12 METHODS Participants. This prospective and longitudinal study was performed at the Clinic of Neurology, Skåne University Hospital, Sweden (part of the Swedish BioFinder Study). The study participants are primarily recruited from the southern region of Sweden. Study participants have been recruited since 2008 and they are followed with repeated neurologic, psychiatric, and cognitive assessments and collection of CSF and blood samples. In this first substudy, we included 42 patients with PD (without dementia) with lumbar puncture at baseline who had been followed for a minimum of 2 years. We also included 69 neurologically healthy controls with lumbar puncture. The controls were primarily spouses or relatives of patients in the study. Controls were only used for baseline comparisons of biomarker levels. Patients with PD met the National Institute of Neurological Disorders and Stroke Diagnostic Criteria for PD. 13 At baseline and during the follow-up after 2 years, the patients were examined by a physician experienced in movement disorders and registered nurse using, among other scales, the Unified Parkinson's Disease Rating Scale, Part III (UPDRS-III), the Hoehn and Yahr Scale, and the Timed Up and Go (TUG) test. [14] [15] [16] The study participants' cognitive function was assessed using the Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale (ADAS) items 1-3 (measure of episodic memory delayed recall), A Quick Test of Cognitive Speed (AQT; measure of cognitive processing speed), and the 1-minute Animal Fluency test. [17] [18] [19] [20] At each study visit, a thorough medical history was taken and the patients underwent extensive testing in both motor symptoms and cognition. The baseline data of the study participants in the present study have previously been described in Hall et al., 5 2012, where they were part of a larger cohort.
Standard protocol approvals, registrations, and patient consents. All individuals gave informed written consent.
The study procedure was approved by the local ethics committee at Lund University Sweden and conducted according to the Helsinki Declaration.
CSF samples. CSF samples were obtained by lumbar puncture in the L3-4 or L4-5 interspace with the patient sitting, nonfasting. The samples was collected in polypropylene tubes and gently mixed to avoid gradient effects. All samples were centrifuged within 30 minutes at 14°C at 2,000g for 10 minutes to remove cells and debris, and then stored in aliquots at 280°C pending biochemical analysis. The levels of Ab 42 , tau, p-tau, aSyn, NFL, and hemoglobin were determined as previously described. 5 Statistical analysis. The statistical analyses were accomplished with SPSS for Windows, version 20.0 (IBM Corp., Armonk, NY). To compare demographic and CSF baseline data between groups, Mann-Whitney U test was used for continuous variables. Pearson x 2 test was used to compare proportions. Univariate associations between 2 continuous variables were analyzed using the Pearson r (normally distributed variables) or Spearman r (skewed variables and/or ordinal data). We used standard linear regressions to test associations between scores on clinical assessment scales (dependent variables) and CSF biomarkers, adjusting for age, sex, disease duration, and levodopa-equivalent daily dose (LEDD). 21 Because of the bimodal distribution of Ab 42 , this measure was also dichotomized using 550 ng/L as cutoff. 22 Here, Student t test was used to compare change in scores on clinical assessment scales, and analysis of covariance was used to adjust for covariates. Before parametric analyses, skewed data were normalized using log-transformation or, in the case of change on clinical assessment scores, using Blom's method. 23 When analyzing aSyn, all subjects with hemoglobin levels .1,000 ng/L were excluded. RESULTS Demographics. Demographics, clinical characteristics, and CSF biomarker levels of study participants are given in tables 1 and 2. Patients with PD had significantly lower levels of aSyn, tau, and p-tau compared with controls (table 2). In the control group, there were no sex differences in any of the biomarker levels. In the control group, higher age correlated with NFL (R s 5 0.580, p , 0.001) but not with any of the other CSF biomarkers in the control group. None of the Higher baseline levels of CSF aSyn correlated with worsening in cognitive processing speed (AQT) over the subsequent 2-year period (R s 5 0.373, p 5 0.030) and this correlation remained significant when correcting for age, sex, disease duration, and LEDD (b 5 0.423, p 5 0.018) ( figure 3A) .
We found no associations between baseline CSF levels of tau, p-tau, or NFL and subsequent cognitive decline when adjusting associations for confounding factors. Correlations between CSF biomarkers and motor progression over 2 years in the PD group. Higher baseline levels of CSF aSyn within the PD group were associated with worsening in motor symptoms over 2 years. We found that higher CSF aSyn correlated with increase in Hoehn and Yahr score over 2 years (R s 5 0.361, p 5 0.033) and this result remained significant when correcting for age, sex, disease duration, and LEDD (b 5 0.394, p 5 0.043). Higher CSF aSyn also correlated with an increase in UPDRS-III score during follow-up (R s 5 0.503, p 5 0.002), even after correcting for age, sex, disease duration, and LEDD (b 5 0.449, p 5 0.013) ( figure 3B ). Finally, higher aSyn levels were associated with a prolonged TUG test (R s 5 0.515, p 5 0.002), which remained significant when correcting for age, sex, disease duration, and LEDD (b 5 0.406, p 5 0.023). Furthermore, higher baseline levels of CSF p-tau were associated with worsening in motor symptoms over 2 years. We found that higher CSF p-tau correlated with an increase in Hoehn and Yahr score (R s 5 0.378, p 5 0.018) and this result remained significant when correcting for age, sex, disease duration, and LEDD (b 5 0.366, p 5 0.038). CSF levels of p-tau also correlated with an increase in UPDRS-III score (R s 5 0.332, p 5 0.039), which was still significant after correcting for age, sex, disease duration, and LEDD (b 5 0.350, p 5 0.045) ( figure 3C ). Tau showed a tendency toward correlating with change in UPDRS score when correcting for age, sex, disease duration, and LEDD (b 5 0.326, p 5 0.053).
We found no significant associations between baseline CSF levels of Ab 42 or NFL and subsequent deterioration in motor symptoms when adjusting associations for confounding factors (data not shown). DISCUSSION In the present prospective and longitudinal study, we found that high levels of aSyn at baseline were associated with subsequent worsening of cognitive processing speed (AQT) and motor symptoms (UPDRS-III, Hoehn and Yahr, and TUG) over 2 years in patients with PD. Also, increased CSF p-tau levels were associated with worsening in motor performance (UPDRS-III and Hoehn and Yahr). Finally, decreased baseline CSF levels of Ab 42 (reflecting cerebral amyloid pathology) were associated with worsening of memory functioning during follow-up (ADAS-cog delayed memory recall).
A quite expected result was that lower levels of Ab 42 predicted worsening of delayed memory recall. In line with this finding, a few cross-sectional studies indicate that Ab 42 is decreased in PD dementia, and longitudinal studies have shown that reduced CSF Ab 42 is a predictor of cognitive decline/dementia in PD. [7] [8] [9] [10] [24] [25] [26] Recently, Parnetti et al. 10 showed that low CSF Ab 42 was associated with a higher rate of decline in global cognition. It is interesting to note that in the present study, reduced CSF Ab 42 predicted subsequent memory impairment, a feature associated with a more AD-like phenotype, and not decline in other cognitive measures (e.g., measures of cognitive processing speed). Reduced Ab 42 levels in CSF most likely reflect increased cortical accumulation of Ab aggregates, as shown in healthy elderly individuals and cases with AD or PD. [27] [28] [29] Indeed, neuropathologic studies have revealed that cerebral amyloid pathology is frequent in many cases with PD dementia. 30, 31 The lack of association of tau-related markers with memory impairment speaks against AD as the underlying process explaining the Ab 42 -memory impairment relationship in our cohort.
Several studies, including the present one, have shown that CSF aSyn is decreased in patients with PD compared with controls, which can be explained by the cerebral accumulation of aSyn in, e.g., Lewy bodies. 2, 4, 5 However, we show that increased levels of aSyn in CSF within the PD group might predict future worsening in cognitive processing speed and motor symptoms. aSyn is a protein localized in the presynaptic nerve terminal. It is associated with synaptic vesicles and is believed to have a role in the regulation of transmitter release, synaptic function, and plasticity. 32, 33 We therefore hypothesize that a greater synaptic degeneration, as one would expect to be present in the brain of patients with PD with more rapid disease progression, could lead to a greater release of aSyn into the interstitial fluid and CSF. This hypothesis is supported by previous studies showing increased CSF levels of aSyn in AD as well as Creutzfeldt-Jakob disease. 2, 4, 5, 34 It is also supported by the observed correlations between CSF levels of aSyn and markers reflecting neurodegeneration, such as tau and NFL (figure 1). 3, 6 However, animal and cell studies are needed to show whether increased CSF levels of aSyn merely reflect ongoing neurodegeneration or more complex changes in the cerebral metabolism of aSyn, such as changed active secretion of the protein from affected neurons. Our results are in line with a recent study from the DATATOP cohort in which increased CSF aSyn predicted worsening of cognitive function, although the authors did not find any correlations between aSyn and progression of motor symptoms. 11 The somewhat divergent results might be explained by differences in study design. For example, the disease duration of the cases included in the present study was longer, and motor deterioration often becomes more evident in patients with longer disease duration. Another recent study on baseline biomarkers in relation to cognitive decline by Parnetti et al. 10 did not find an association between the levels of aSyn and future global cognitive decline as measured by the MMSE and Montreal Cognitive Assessment. In the present study, we observed an association between change in AQT over time and higher baseline levels of aSyn within the PD group. AQT primarily measures cognitive processing speed, which is affected early in PD, but not specifically measured by MMSE or Montreal Cognitive Assessment.
In the present study, motor progression was associated not only with increased CSF aSyn, but also increased CSF p-tau. The tau-encoding gene (MAPT) and the aSyn-encoding gene (SNCA) have been linked to PD through genome-wide associations studies. 35 A recent study found PD risk alleles of MAPT to be associated with overall parkinsonism. 36 There seem to be molecular interactions between aSyn and tau pathology. Tau can be found in Lewy bodies in sporadic PD brains. 37 Indeed, there is evidence that certain aSyn fibrils might induce aggregation of tau by cross-seeding. 38 Furthermore, aSyn has been shown to contribute to the phosphorylation of tau in various mouse and human models, and increased levels of p-tau can be found in the striatum of patients with PD and PD dementia. 39, 40 In this study, we show that aSyn levels correlate with p-tau, which is in line with previous studies and connect well with the notion that tau pathology can be associated with synucleinopathy in PD. 3 One could argue that in a more aggressive disease with higher levels of aSyn, there is also a higher rate of phosphorylation of tau leading to increased levels of p-tau, which in turn might aggravate the disease, leading to a vicious cycle. It is interesting to note that elevated CSF p-tau, which is firmly linked to cognitive decline in AD, correlated to worsening of motor symptoms in PD, which, again, suggests that the pathogenic pathways are distinct in PD and AD, at least regarding the brain regions that are affected. In this study, we show that higher CSF levels of aSyn and p-tau in the PD group are associated with faster progression of motor symptoms in PD. Furthermore, increased aSyn and decreased Ab 42 in CSF predict different aspects of cognitive decline. One limitation of the present prospective and longitudinal study is the relatively small group of patients who have been followed for at least 2 years, and our results need to be replicated in a larger cohort. 
